NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015):...

Area of Science:

• Oncology
• Clinical Trials
• Cancer Therapeutics

Background:

• Malignant pleural mesothelioma is an aggressive cancer with limited treatment options post-first-line chemotherapy.
• NGR-hTNF is a vascular-targeting agent designed to enhance chemotherapy penetration and T-cell infiltration.
• This study investigated NGR-hTNF in patients with advanced malignant pleural mesothelioma.

Purpose of the Study:

• To evaluate the efficacy and safety of NGR-hTNF combined with best investigator choice treatment.
• To determine if NGR-hTNF improves overall survival in patients with malignant pleural mesothelioma who progressed on first-line therapy.

Main Methods:

• A randomized, double-blind, placebo-controlled Phase 3 trial (NGR015) involving 400 patients.
• Patients received NGR-hTNF or placebo intravenously, plus investigator-chosen chemotherapy or best supportive care.
• Primary endpoint was overall survival in the intention-to-treat population.

Main Results:

• Overall survival did not differ significantly between the NGR-hTNF group (median 8.5 months) and the placebo group (median 8.0 months).
• Grade 3 or worse adverse events were reported in 70% of the NGR-hTNF group versus 61% of the placebo group.
• No significant difference in treatment-related serious adverse events or deaths was observed between groups.

Conclusions:

• The study did not meet its primary endpoint of improving overall survival.
• Hypothesis-generating findings from subgroup analyses suggest a need for confirmatory trials.
• NGR-hTNF did not demonstrate efficacy as a second-line treatment for malignant pleural mesothelioma in this trial.